In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
The global health landscape faces challenges and innovations, with the European review of Alzheimer's drug Leqembi, Ebola ...
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...
Verywell Health on MSN2d
New Maintenance Dosing Option for Alzheimer's Drug Leqembi Offers FlexibilityThe Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
GlobalData on MSN3d
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosingThe FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback